

Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group

Authors

Kari Lenita Falck Moore,¹⁻⁴ Sæmundur Rögnvaldsson,^{5,6} Agoston G. Szabo,^{7,8} Vilmantė Vaitekėnaitė,⁹ Diana Loigom,¹⁰ Anna Genell,¹¹ Jonathan Thorsen,¹² Jakob N. Nørgaard,¹⁻³ Sigrún Thorsteinsdóttir,^{6,7} Dorota Knut-Bojanowska,¹³ Anna Lysén,¹ Fredrik Schjesvold,¹ Valdas Peceliunas,^{9,14} Ain Kaare,¹⁵ Katrin Palk,¹⁰ Maris Pärnat,¹⁵ Alexander Sigurdsson,¹⁶ Annette J. Vangsted⁷ and Cecilie H. Blimark^{17,18} on behalf of the Nordic Myeloma Study Group

¹Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; ²Institute of Clinical Medicine, University of Oslo, Oslo, Norway; ³K.G. Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway; ⁴Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway; ⁵Landspítali University Hospital, Reykjavik, Iceland; ⁶Faculty of Medicine, University of Iceland, Reykjavik, Iceland; ⁷Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ⁸Department of Hematology, Vejle Hospital, Vejle, Denmark; ⁹Center for Hematology, Oncology, and Transfusiology, National Cancer Center Affiliate, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; ¹⁰Center of Hematology, North Estonia Medical Center Foundation, Tallinn, Estonia; ¹¹Regional Cancer Center of the Western Region,

Sahlgrenska University Hospital, Gothenburg, Sweden; ¹²Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark; ¹³Department of Hematology, Uddevalla Hospital, Uddevalla, Sweden; ¹⁴Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; ¹⁵Department of Hematology and Bone Marrow Transplant, Tartu University Hospital, Tartu, Estonia; ¹⁶Reykjavík Primary Health Care Center, Reykjavik, Iceland; ¹⁷Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden and ¹⁸Department of Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Correspondence:

K. L. FALCK MOORE – kari.lenita.falck.moore@sus.no

<https://doi.org/10.3324/haematol.2025.287344>

Received: January 31, 2025.

Accepted: August 7, 2025.

Early view: September 4, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Supplemental Table S1: Proportion of patients treated with upfront autologous stem cell transplantation 2008-2020, by country, age group and sex

Age group	Total population (n)				Denmark				Estonia			
	Not ASCT		ASCT		Not ASCT		ASCT		Not ASCT		ASCT	
	Men	Women	Men	Women	Men	Women	Men	Women	Men	Women	Men	Women
18-65	1066	758	2494	1688	221	147	584	435	49	62	105	101
66-70	1242	961	526	366	307	198	143	119	50	56	19	23
71-75	1960	1349	40	19	460	355	5	4	63	72	5	5
Total	4268	3068	3060	2073	988	700	732	558	162	190	129	129

Age group	Iceland				Lithuania				Norway				Sweden			
	Not ASCT		ASCT		Not ASCT		ASCT		Not ASCT		ASCT		Not ASCT		ASCT	
	Men	Women	Men	Women	Men	Women	Men	Women	Men	Women	Men	Women	Men	Women	Men	Women
18-65	24	23	30	22	NA	NA	222	222	402	299	657	437	370	227	1118	693
66-70	15	13	6	7	NA	NA	40	41	385	282	96	64	485	412	262	153
71-75	0	0	5	1	NA	NA	5	10	570	344	7	2	867	578	23	8
Total	39	36	41	30	NA	NA	267	273	1357	925	760	503	1722	1217	1403	854

ASCT; Autologous stem cell transplantation. NA; Not available

Statistical analysis by Chi-squared tests: There is no statistically significant difference between the proportion of men and women transplanted for the total population or any of the age subgroups.

Supplemental Table S2: Characteristics and induction regimen of population treated with upfront ASCT 2008-2020, by country

	Total	Denmark	Estonia	Iceland	Lithuania	Norway	Sweden
Total population treated with upfront ASCT	5753	1292	258	83	540	1323	2257
Female, n (%)	2383 (41%)	559 (43%)	129 (50%)	37 (45%)	273 (51%)	531 (40%)	854 (38%)
Mean age at diagnosis (years, standard deviation)	58.7 (7.7)	59.5 (7.7)	58.1 (8.3)	59.6 (9.17)	58 (8.2)	58 (7.3)	58.9 (7.8)
Median time to ASCT (days)	-	141	169	171	168	151	139
18-65 years, n (%)	4676 (81%)	1019 (79%)	206 (80%)	55 (66%)	444 (82%)	1141 (86%)	1811 (80%)
66-70 years, n (%)	993 (17%)	262 (20%)	42 (16%)	21 (25%)	81 (15%)	172 (13%)	415 (18%)
71-75 years, n (%)	82 (1.4%)	9 (0,7%)	10 (4%)	7 (8%)	15 (3%)	10 (0,8%)	31 (1,4%)
≥76 years, n (%)	2 (0.0%)	2 (0,2%)	0	0	0	0	0
Myeloma characteristics at diagnosis							
ISS available (n)	4839 (84%)	1152 (89%)	258 (100%)	46 (55%)	464 (86%)	1074 (81%)	1845 (82%)
ISS I (n)	1851 (38%)	541 (47%)	90 (35%)	29 (63%)	162 (35%)	455 (42%)	574 (31%)
ISS II (n)	1680 (35%)	287 (25%)	86 (33%)	13 (28%)	117 (25%)	350 (33%)	827 (45%)
ISS III (n)	1308 (27%)	324 (28%)	82 (32%)	4 (9%)	185 (40%)	269 (25%)	444 (24%)
Anemia* (n, %)	2000 (35%)	412 (32%)	112 (43%)	15 (18%)	173 (32%)	659 (50%)	629 (28%)
Hypercalcemia** (%)	1053 (18%)	272 (21%)	51 (20%)	51 (10%)	80 (15%)	187 (14%)	455 (20%)
Renal failure***	716 (12%)	122 (9%)	63 (24%)	8 (10%)	74 (14%)	163 (12%)	286 (13%)
Skeletal disease †	4312 (75%)	1009 (78%)	218 (84%)	48 (58%)	389 (72%)	1048 (79%)	1600 (71%)
FISH performed (%)	3123 (54%)	717 (55%)	184 (71%)	44 (53%)	311 (58%)	667 (50%)	1200 (53%)
High risk FISH (%)	565 (10%)	180 (14%)	39 (15%)	16 (19%)	56 (10%)	146 (20%)	128 (6%)
Induction regimens							
PI-based	3206 (56%)	879 (68%)	154 (60%)	69 (83%)	63 (12%)	736 (56%)	1305 (58%)
IMiD and PI-based	1589 (28%)	225 (17%)	80 (31%)	1 (1%)	227 (42%)	465 (35%)	591 (26%)
IMiD-based	347 (6%)	4 (0%)	3 (1%)	1 (1%)	231 (43%)	10 (1%)	98 (4%)
CD38-antibody-based	64 (1%)	7 (1%)	0 (0%)	0 (0%)	0 (0%)	4 (0%)	53 (2%)
Other (including chemotherapy-based)	529 (9%)	177 (14%)	21 (8%)	12 (14%)	19 (4%)	108 (8%)	192 (9%)
Missing	9 (0%)	0 (0%)	(0%)	0 (0%)	0 (0%)	0 (0%)	9 (0%)

*Anemia; Hemoglobin <100 g/l or Hemoglobin >20 g/l below lower limit of normal.

**Hypercalcemia; Ionized calcium >1.35 mmol/l or total calcium >2.75 mmol/l.

*** Renal failure; Creatinine >177 µmol/l or creatinine clearance <40 ml/min.


†Skeletal disease; ≥1 osteolytic lesion.

‡ High risk FISH; del17p and/or t(4;14) and/or t(14;16).

ASCT; Autologous stem cell transplantation. FISH; Fluorescence in situ hybridization. IMiD; Immunomodulatory drug. ISS; International Staging System.

PI; proteasome inhibitor.

Supplemental Figure 1: Overall survival at 1 year, 3 years and 5 years of all patients treated with autologous stem cell transplantation.



All transplanted patients from all 6 countries.